Table S2. Univariate and multivariate analysis of predictive factor for progression-free and LC for PLLs.
| Characteristics | PFS | LC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P Value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Type of primary | 0.47 | ||||||||||
| De novo | 2.09 (0.90–4.85) | 0.08 | 1.17 (0.45–3.04) | 0.73 | 2.97 (0.86–10.23) | 0.08 | 1.65 (0.41–6.56) | ||||
| Recurrent | – | – | – | – | – | – | – | ||||
| Histology | – | ||||||||||
| Squamous | 0.19 (0.39–2.15) | 0.84 | – | – | 0.38 (0.09–1.51) | 0.17 | – | ||||
| Non-squamous | – | – | – | – | – | – | – | ||||
| SUVmax | – | ||||||||||
| <6.9 | 0.57 (0.22–1.50) | 0.25 | – | – | 0.31 (0.05–1.67) | 0.17 | – | ||||
| >6.9 | – | – | – | – | – | – | – | ||||
| SUVmax (continuous) | 1 (0.93–1.08) | 0.81 | – | – | 1.07 (0.96–1.19) | 0.17 | – | ||||
| GTV | – | ||||||||||
| <14 mL | 0.71 (0.29–1.71) | 0.44 | – | – | 0.79 (0.22–2.78) | 0.71 | – | ||||
| >14 mL | – | – | – | – | – | – | – | ||||
| GTV (continuous) | 0.99 (0.95–1.03) | 0.70 | – | – | 0.99 (0.93–1.06) | 0.88 | – | – | |||
| SABR-duration | 0.10 | ||||||||||
| <9 days | 1.06 (0.45–2.49) | 0.89 | – | – | 0.31 (0.09–1.08) | 0.06 | 0.16 (0.02–1.45) | ||||
| ≥9 days | – | – | – | – | – | – | – | ||||
| SABR-duration (continuous) | 1.03 (0.93–1.16) | 0.49 | – | – | 0.84 (0.67–1.04) | 0.12 | – | – | |||
| Interval to SABR§ | 0.15 | ||||||||||
| <60 days | 0.57 (0.24–1.34) | 0.19 | – | – | 0.27 (0.07–1.05) | 0.05 | 0.33 (0.07–1.52) | ||||
| >60 days | – | – | – | – | – | – | – | ||||
| Interval to SABR§ (continuous) | 1 (0.99–1.01) | 0.15 | – | – | 0.98 (0.96–1.00) | 0.19 | – | – | |||
| No. of fractions | – | ||||||||||
| <5 fractions | 0.92 (0.39–2.15) | 0.84 | – | – | 0.52 (0.15–1.76) | 0.29 | – | ||||
| >5 fractions | – | – | – | – | – | – | – | ||||
| No. of fractions (continuous) | 1.14 (0.92–1.42) | 0.20 | 0.86 (0.59–1.26) | 0.46 | – | ||||||
| Dose per fraction | – | ||||||||||
| <12 Gy | 0.30 (0.12–0.71) | 0.006 | 0.14 (0.02–0.80) | 0.02 | 0.42 (0.12–1.41) | 0.16 | – | ||||
| >12 Gy | – | – | – | – | – | – | – | ||||
| Dose per fraction (continuous) | 0.87 (0.76–1.00) | 0.06 | 1.19 (0.88–1.62) | 0.25 | 0.95 (0.76–1.18) | 0.67 | – | ||||
| Total dose | – | ||||||||||
| <48 Gy | 0.94 (0.40–2.2) | 0.90 | – | – | 0.42 (0.12–1.47) | 0.17 | – | ||||
| >48 Gy | – | – | – | – | – | – | – | ||||
| Total dose (continuous) | 0.99 (0.94–1.05) | 0.94 | – | – | 0.93 (0.86–1.01) | 0.08 | 1.06 (0.86–1.30) | 0.57 | |||
| Prescription IDL | – | ||||||||||
| 80% IDL | 1.19 (0.15–9.00) | 0.86 | – | – | 3.14 (0.39–25.30) | 0.82 | – | ||||
| 60% IDL | – | – | – | – | – | – | – | ||||
| Treatment technique | – | ||||||||||
| 3D | 1.24 (0.48–3.12) | 0.64 | – | – | 0.65 (0.14–3.05) | 0.58 | – | ||||
| IMRT | – | – | – | – | – | – | – | ||||
| BED10 | 0.73 | ||||||||||
| <105 Gy10 | 0.69 (0.23–2.08) | 0.51 | – | – | 0.18 (0.05–0.68) | 0.01 | 0.63 (0.04–8.89) | ||||
| >105 Gy10 | – | – | – | – | – | – | – | ||||
| BED10 (continuous) | 0.98 (0.97–1.00) | 0.14 | – | – | 0.97 (0.95–1.00) | 0.09 | 0.96 (0.0.87) | 0.42 | |||
§, interval to SABR was calculated from the first date of diagnosis (biopsy, PET, CT) to the first day of SABR. LC, local control; PLLs, primary lung lesions; PFS, progression-free survival; CT, computed tomography; HR, hazard ratio; SUVmax, maximal standardized uptake volume; GTV, gross tumor volume; SABR, stereotactic ablative radiotherapy; IDL, isodose line; 3D, three dimensional; IMRT, intensity-modulated radiation therapy; BED10, biologic effective dose at α/β=10 Gy; PET, positron-emission-tomography; CT, computed tomography.